Study on metabolic risk of first-episode acute schizophrenia patients treated with aripiprazole

Xiao-li WU,Fei WEN,Zhi-yong ZHONG,Zi-li HAN

2011-01-01

Abstract:AIM: To study the metabolic risk of first-episode acute schizophrenia patients treated with aripiprazole. METHODS: 31 first-episode acute patients with schizophrenic were enrolled into case group and 44 healthy subjects were enrolled into controle group,all cases accepted treatment with oral aripiprazole.At the baseline and at the end,all patients were checked or tested for weight,waist circumference,waist-to-hipratio(WHR),TC,TG,high density lipoprotein(HDL),low density lipoprotein(LDL),apolipoprotein A1(Apo-Al),apolipoprotein B(Apo-B100),lipoprotein a(LPa),fasting blood glucose(FBS),fasting insulin(INS)and c-peptide(C-P),respectively.The BMI and insulin resistance index(HOMA-IR) were calculated.All indexes were compared and analysed between the case group and controle group,pre and post treatment in the case group.RESULTS:The INS,C-P and HOMA-IR in the case group were significantly higher than those in the control group,there was no significant difference(P<0.05).After treatment,the body weight,BMI,waist circumference,WHR in the case group were increased significantly,there was no significant difference(P<0.05).Copmared with the control group,the TG,INS,C-P,HOMA-IR were significantly increased after treatment in the case group,while aPOA1 was decreased,there is no significant difference(P<0.05).CONCLUSION: There may be some inborn metabolic abnormality in schizophrenia patients themselves.The effects of aripiprazole on glucose and lipid metabolism of first-episode acute schizophrenia are smaller.